264 related articles for article (PubMed ID: 12892952)
21. [Patents and availability of essential drugs].
Carné X
Med Clin (Barc); 2007 Nov; 129(16):617-8. PubMed ID: 18001674
[No Abstract] [Full Text] [Related]
22. [What drug companies actually do].
Tonby K
Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1806. PubMed ID: 17599137
[No Abstract] [Full Text] [Related]
23. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
[No Abstract] [Full Text] [Related]
24. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
25. The role of civil society in protecting public health over commercial interests: lessons from Thailand.
Ford N; Wilson D; Bunjumnong O; von Schoen Angerer T
Lancet; 2004 Feb; 363(9408):560-3. PubMed ID: 14975620
[No Abstract] [Full Text] [Related]
26. Indian biogenerics industry emerges.
Jayaraman KS
Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378
[No Abstract] [Full Text] [Related]
27. Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
Fogel LE; Ray CJ
Expert Opin Ther Pat; 2015 Jan; 25(1):1-4. PubMed ID: 25363310
[TBL] [Abstract][Full Text] [Related]
28. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
[TBL] [Abstract][Full Text] [Related]
29. Trade systems in less-developed countries.
Kamal Smith M; 't Hoen E
Lancet; 2001 May; 357(9268):1624. PubMed ID: 11386324
[No Abstract] [Full Text] [Related]
30. Patents versus patients? Antiretroviral therapy in India.
Havlir DV; Hammer SM
N Engl J Med; 2005 Aug; 353(8):749-51. PubMed ID: 16120852
[No Abstract] [Full Text] [Related]
31. The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be valid.
Garrigues A
J Law Med Ethics; 2004; 32(1):181-4. PubMed ID: 15152443
[No Abstract] [Full Text] [Related]
32. Protection of commercial opportunity.
Wyllie MG
BJU Int; 2012 Feb; 109(3):E8-9. PubMed ID: 22243668
[No Abstract] [Full Text] [Related]
33. Bill C-30: who wins and who loses in Canada's pharmaceutical patent battles?
Hollis A
Expert Opin Ther Pat; 2018 Jan; 28(1):1-3. PubMed ID: 28974123
[No Abstract] [Full Text] [Related]
34. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals.
Babovic S; Wasan KM
J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678
[TBL] [Abstract][Full Text] [Related]
35. TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges.
Orsi F; D'Almeida C; Hasenclever L; Camara M; Tigre P; Coriat B
AIDS; 2007 Oct; 21(15):1997-2003. PubMed ID: 17885289
[No Abstract] [Full Text] [Related]
36. TRIPs revisited.
Ford N
Br J Gen Pract; 2001 Nov; 51(472):948. PubMed ID: 11761222
[No Abstract] [Full Text] [Related]
37. A fair deal for the future: flexibilities under TRIPS.
So AD
Bull World Health Organ; 2004 Nov; 82(11):813. PubMed ID: 15640914
[No Abstract] [Full Text] [Related]
38. Canada ordered to implement WTO ruling against "stockpiling" of generic drugs.
Elliott R
Can HIV AIDS Policy Law Rev; 2000; 5(4):27. PubMed ID: 11833161
[TBL] [Abstract][Full Text] [Related]
39. World Trade Organization wrestles with access to cheap drugs solution.
Loff B
Lancet; 2002 Nov; 360(9346):1670. PubMed ID: 12457799
[No Abstract] [Full Text] [Related]
40. GSK and Boehringer agree to generic AIDS drugs deal.
Nelson K
Lancet; 2003 Dec; 362(9401):2074. PubMed ID: 14700066
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
